Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 22, 2026 | May 26, 2026 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Medical Officer | September 28, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date May 22, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 45,871 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 45,871 · Balance 45,871 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
NEUROCRINE BIOSCIENCES INC
Report date September 28, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,331 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 51,331 F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $102.90 · Expires 2030-02-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.63 · Expires 2031-02-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2032-01-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $136.69 · Expires 2034-12-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $124.12 · Expires 2036-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance Not disclosed F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-28 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award. |
Filing footnotes · ownership attribution and instrument terms
F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.
F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.
F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.
F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.
F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 76,275 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 40,625 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2020 Filed Aug 7, 2020 23:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.84 | $268,225.27 |
DisclosureSEC source: 0001209191-20-045771 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,446 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.21 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $77.81 Strike: $77.81 | $389,050.00 |
DisclosureSEC source: 0001209191-20-038896 · doc4.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,860 Underlying: Common Stock · 5,000 shares Expires 2028-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $130.00 | $650,000.00 |
DisclosureSEC source: 0001209191-20-038896 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $77.81 | $389,050.00 |
DisclosureSEC source: 0001209191-20-038896 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.47 | $192,376.33 |
DisclosureSEC source: 0001209191-20-026072 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.63 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 223 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,623 | $103.31 | $167,675.38 |
DisclosureSEC source: 0001209191-20-008518 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,452 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.22 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 8,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007688 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,504 Underlying: Common Stock · 8,504 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:49 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 53,678 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007688 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,678 Underlying: Common Stock · 53,678 shares Expires 2030-02-06 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,632 | $111.11 | $292,444.94 |
DisclosureSEC source: 0001209191-20-003043 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,991 F1 · kind: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 8, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.04 to $111.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 480 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 274 shares on February 28, 2019 and 206 shares on August 30, 2019. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock · Derivative | 12,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008648 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,339 Underlying: Common Stock · 12,339 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 66,673 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008648 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,673 Underlying: Common Stock · 66,673 shares Expires 2029-02-07 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,857 | $84.09 | $156,158.66 |
DisclosureSEC source: 0001209191-19-003276 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,143 F1 · kind: Sale of 1,857 shares of common stock issued upon vesting of 5,000 restricted stock units on January 8, 2019 to cover payroll and withholding taxes, with the balance of the shares (3,143) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $82.95 to $84.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 18,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008221 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2020-02-05 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008221 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003127 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:57 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 70,000 | $0.00 Strike: $77.81 | $0.00 |
DisclosureSEC source: 0001209191-18-003127 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-08 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.